Uploaded April 2024 | Updated November 2026, 2 days ago
Vinton “Vint” Cerf, Ph.D., is the special guest for the 2024 J. Edward Rall Cultural Lecture, The Promises and Perils of AI in Biomedical Research and Health Care Delivery. Dr. Cerf is known as one of the “fathers of the internet” and currently serves as vice president and Chief Internet Evangelist for Google. NIH Director Dr. Monica Bertagnolli will hold a conversation with Dr. Cerf about AI and machine learning, especially as it relates to her vision for delivering evidence-based care to all people and invite him to respond to questions from NIH staff submitted in advance on the lecture topic. Vint Cerf and his collaborator Robert Kahn received the U.S. National Medal of Technology from President Clinton in 1997 for founding and developing the internet. Dr. Cerf later received the Presidential Medal of Freedom from President George W. Bush, the Marconi Prize, and the Turing Award, among many other awards. He is a thought leader and a public face in the internet world for Google, where he contributes to global policy development and continued standardization of the internet. Long a champion of internet neutrality and full accessibility, Cerf in recent years has voiced his concern about and has proposed possible solutions to combat dangers such as the long-term durability of digital storage, the spread of misinformation, and rapid growth of AI. The Rall Cultural Lecture is named in honor of Dr. Joseph "Ed" Rall, who helped to define NIH's modern intramural research program and establish a stable academic-like and culturally rich community within a rapidly expanding government agency.
For more information go to oir.nih.gov/wals/nih-directors-wednesday-afternoon-lecture-series-2023-2024/promises-perils-ai-biomedical-research-health-care-delivery
Vinton “Vint” Cerf, Ph.D., is the special guest for the 2024 J. Edward Rall Cultural Lecture, The Promises and Perils of AI in Biomedical Research and Health Care Delivery. Dr. Cerf is known as one of the “fathers of the internet” and currently serves as vice president and Chief Internet Evangelist for Google. NIH Director Dr. Monica Bertagnolli will hold a conversation with Dr. Cerf about AI and machine learning, especially as it relates to her vision for delivering evidence-based care to all people and invite him to respond to questions from NIH staff submitted in advance on the lecture topic. Vint Cerf and his collaborator Robert Kahn received the U.S. National Medal of Technology from President Clinton in 1997 for founding and developing the internet. Dr. Cerf later received the Presidential Medal of Freedom from President George W. Bush, the Marconi Prize, and the Turing Award, among many other awards. He is a thought leader and a public face in the internet world for Google, where he contributes to global policy development and continued standardization of the internet. Long a champion of internet neutrality and full accessibility, Cerf in recent years has voiced his concern about and has proposed possible solutions to combat dangers such as the long-term durability of digital storage, the spread of misinformation, and rapid growth of AI. The Rall Cultural Lecture is named in honor of Dr. Joseph "Ed" Rall, who helped to define NIH's modern intramural research program and establish a stable academic-like and culturally rich community within a rapidly expanding government agency.
For more information go to oir.nih.gov/wals/nih-directors-wednesday-afternoon-lecture-series-2023-2024/promises-perils-ai-biomedical-research-health-care-delivery
![Not Your Father’s Heart Disease: The Herstory and the NHLBI WISE
The research of C. Noel Bairey Merz, MD, focuses on heart disease in women, preventive cardiology, coronary physiology/pathophysiology and advanced cardiac imaging, as well as alternative and complementary medicine approaches to heart disease. Cardiovascular disease (CVD) is the leading cause of death in the US and on the planet, yet up to 70% of patients undergoing invasive angiography do not have obstructive coronary artery disease (CAD), more common in women than in men, as described by US and multi-national consensus documents. Although CMD has been documented over several decades, variability in symptom and stress testing characteristics lead to the widely held notion that these patients were “low risk”, very often receiving no specific therapy and dismissal from sub-specialty care. Evidence from the WISE original multicenter cohort, documented a higher risk of adverse events (e.g. death, myocardial infarction [MI], stroke, or hospitalization for heart failure [HF] or angina) emerging after 4-years of follow-up, comparable to patients with obstructive CAD, and higher in African American women25. Others have confirmed these findings and extended them to men (~20%). We have documented that most of these patients have coronary endothelial dysfunction, extensive but non-obstructive coronary atherosclerosis by intravascular ultrasound (IVUS), CMD, and myocardial ischemia. CMD, ischemia on stress testing, and angina persisting at 1-yr follow-up, identify patients at higher risk for adverse outcomes, most frequently hospitalization for HF, with preserved left ventricular (LV) ejection fraction (EF), i.e. HFpEF. Estimates from ACC/NCDR and WISE databases, indicate there are at least 3-4 million women and 1-2 million men in the US alone with INOCA who incur health-care costs similar to many with obstructive CAD. CMD may result from changes in function and/or structure of the coronary microcirculation, and in the absence of upstream obstructive CAD, is poorly understood mechanistically. Termed ischemia with no obstructive CAD (INOCA) and myocardial infarction with no obstructive CAD (MINOCA), these syndromes are increasingly observed in women, as well as men. Pharmacologic probe trials support anti-atherosclerotic and anti-ischemic therapies, and our ongoing clinical trial (WARRIOR NCT03417388) is testing high intensity statin, maximally-tolerated angiotensin-converting-enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) and low dose aspirin in women with INOCA for reduction of major adverse CV events (MACE); results are expected in 2025.
For more information go to https://oir.nih.gov/wals Not Your Father’s Heart Disease: The Herstory and the NHLBI WISE](https://i.ytimg.com/vi/plNCOgIPTDA/mqdefault.jpg)

![Forging a New Future: Inclusion of People with Disabilities in Technology Research and Development
Air date: Wednesday, January 11, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS]
When technology is properly created and applied it can be of tremendous benefit to people with disabilities. People with disabilities along with their allies know better than any other how being involved in the planning from day one is critical to a successfully accessible product, regardless of how many years in the future it lies. Dr. Cooper will present on technologies and research that he and members of the team at the Human Engineering Research Laboratories are working on ranging from Apps, cushions, homes, robots, and wheelchairs. Dr. Cooper will also speak about innovative education programs to build research and development capacity among people with disabilities and veterans.
Dr. Rory Cooper is the founding director at the Human Engineering Research Laboratories, a VA Rehabilitation Research and Development Center of Excellence in partnership with Pitt. Also, he serves as co-director of the NSF Quality of Life Technology Engineering Research Center, a joint Pitt-Carnegie Mellon University venture.
For more information go to https://oir.nih.gov/wals
Author: Rory Cooper, Ph.D., University of Pittsburgh
Permanent link: https://videocast.nih.gov/watch=46052 Forging a New Future: Inclusion of People with Disabilities in Technology Research and Development](https://i.ytimg.com/vi/qOF6gNww1m0/mqdefault.jpg)



![Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme
Air date: Wednesday, February 1, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture [WALS]
See https://en.wikipedia.org/wiki/Helen_Blau
For more information go to https://oir.nih.gov/wals
Author: Helen Blau, Ph.D., Stanford Medicine
Permanent link: https://videocast.nih.gov/watch=46058 Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme](https://i.ytimg.com/vi/rPVoQesTplU/mqdefault.jpg)


![Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras
Air date: Wednesday, March 8, 2023, 2PM
Description: NIH Directors WALS Lecture [WALS]
Kevan Shokat is a chemist who discovers drugs against some of the most common drivers of human cancers. He is best known for targeting a mutation that drives more than 1 in 10 lung cancers, opening up a new arena of cancer treatment discovery. The target, K-Ras, is the most common driver of cancer, and was considered “undruggable” by most cancer researchers after 40 years of failed attempts to block its function. Dr. Shokat’s discovery of a K-Ras blocker broke through this decades-old barrier and threw open the doors to a new class of cancer treatments. Lecture summary: 1. To understand the chemical, biochemical and cellular challenges to identifying a drug to target K-Ras mutant tumors 2. To learn how to discover drugs which only target oncogenes in cancer cells while sparing signaling in the rest of the body using covalent chemistry. 3. To learn about new approaches for combination therapy in cancer including re-activation of the tumor suppressor p53 and engaging the immune cells to overcome resistance to targeted therapies.
https://cancer.ucsf.edu/people/shokat.kevan
For more information go to https://oir.nih.gov/wals
Author: Kevan Shokat, Ph.D., University of California, Berkeley
Permanent link: https://videocast.nih.gov/watch=46070 Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras](https://i.ytimg.com/vi/rtR3yl5U4yk/mqdefault.jpg)
